Mitochondrial defect in Huntington's disease caudate nucleus

Annals of Neurology

Volumn 39, Issue 3, 1996, Pages 385-389

  Gu, M ^a   Gash, M T ^a   Mann, V M ^a   Javoy Agid, F ^b   Cooper, J M ^a   Schapira, A H V ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; MITOCHONDRION; OXIDATIVE PHOSPHORYLATION; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY CHAIN;

AGED; CAUDATE NUCLEUS; CHROMOSOMES, HUMAN, PAIR 4; CULTURE TECHNIQUES; DNA, MITOCHONDRIAL; ELECTRON TRANSPORT COMPLEX III; ENERGY METABOLISM; GENE EXPRESSION; GLUTAMIC ACID; HUMANS; HUNTINGTON DISEASE; MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); RNA, MESSENGER;

EID: 0029875381     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410390317     Document Type: Article

References (20)

1. Albin RL, Tagle DA Genetics and molecular biology of Huntington's disease. Trends Neurosci 1995;18:11-14
2. Brennan WA, Bird ED, Aprille JR. Regional mitochondrial respiratory activity in Huntington's disease brain. J Neurochem 1985;44:1948-1950
3. Kuwert T, Lange HW, Boecker H, et al. Striatal glucose consumption in chorea-free subjects at risk of Huntington's disease. J Neurol 1993;241:31-36
4. Martin WRW, Clark C, Ammann W, et al. Cortical glucose metabolism in Huntington's disease. Neurology 1992;42:223-229
5. Jenkins B, Koroshetz, W, Beal MF, Rosen B. Evidence for an energy metabolism defect in Huntington's disease using localized proton spectroscopy. Neurology 1993;43:2689-2695.
6. Koroshetz WJ, Jenkins B, Rosen B, Beal MF. Evidence for a metabolic disorder in Huntington's disease. Neurology 1994;44:A338
7. Mann VM, Cooper JM, Javoy-Agid F, et al. Mitochondrial function and parental sex effect in Huntington's disease. Lancet 1990;336:749
8. Parker WD, Boyson SJ, Luder AS, Parks JK. Evidence for a defect in NADH: ubiquinone oxidoreductase (complex I) in Huntington's disease. Neurology 1990;40:1231-1234
9. 1 reductase (complex 1) deficiency in Parkinson's disease. J Neurochem 1990;55:2142-2145
10. Ragan CI, Wilson MT, Darley-Usmar VM, Lowe PN. Subfractionation of mitochondria, and isolation of the proteins of oxidative phosphorylation. In: Darley-Usmar VM, Rickwood D, Wilson MT, eds. Mitochondria, a practical approach. London: IRL Press, 1987:79-112
11. Krige D, Carroll MT, Cooper JM, et al. Platelet mitochondrial function in Parkinson's disease. Ann Neurol 1992;32:782-788
12. Smith PR, Cooper JM, Govan GG, et al. Smoking and mitochondrial function: a model for environmental toxins. Q J Med 1993;86:657-660
13. Trottier Y, Devys D, Imbert G, et al. Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nature Genet 1995;10:104-110
14. Beal MF. Neurochemistry and toxin models in Huntington's disease. Curr Opin Neurol 1994;7:542-547
15. Simpson JR, Isacson O. Mitochondrial impairment reduces the threshold for in vivo NMDA-mediated neuronal death in the striatum. Exp Neurol 1993;121:57-64
16. Taylor-Robinson SD, Weeks RA, Satgentoni J, et al. Evidence for glutamate excitotoxicity in Huntington's disease with proton magnetic resonance spectroscopy. Lancet 1994;343:1170
17. Ludolph AC, He F, Spencer PS, et al 3-Nitropropionic acid: exogenous animal neurotoxin and possible human striatal toxin. Can J Neurol Sci 1991;18:492-498
18. Ludolph AC, Seelig M, Ludolph A, et al. 3-Nitropropionic acid decreases cellular energy levels and causes neuronal degeneration in cortical explants. Neurodegeneration 1992;1:155-161
19. Beal MR, Brouillet E, Jenkins B, et al. Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J Neurochem 1993;61:1147-1150
20. Greene JG, Porter RHP, Eller RV, Greenamyre JT. Inhibition of succinate dehydrogenase by malonic acid produces an "excitotoxic" lesion in rat striatum. J Neurochem 1993;61:1151-1154